-
Line treatment of gastric cancer/esophageal cancer BMS immunocombination therapy reaches phase 3 clinical endpoint
Time of Update: 2020-09-11
addition, the CheckMate-649 study evaluated the effectiveness of Odivo's combined epipentherapy chemotherapy for patients with stomach cancer, gastroesophageal connecting cancer, or esophageal adenocarcinoma.
-
First-line treatment of stomach cancer and esophageal cancer! Odivo (Navuliyu monoanti) and chemotherapy programme Phase III clinical data: significantly improved total survival and non-progression survival.
Time of Update: 2020-09-11
addition, the CheckMate-649 study evaluated the effectiveness of Odivo's combined epipentherapy chemotherapy for patients with stomach cancer, gastroesophageal connecting cancer, or esophageal adenocarcinoma.
-
First-line immunotherapy for lung cancer! Cinda Bio/Lilly Daboshu ® treatment of non-scaly non-small cell lung cancer by the National Drug Administration!
Time of Update: 2020-09-11
12, 2020 // -- Innovent Biologics and Eli Lilly recently jointly announced that the National Drug Administration (NMPA) has officially accepted PD-1 Inhibitor Dabershu ® (SNDA), a new adaptive application (sNDA), combined with the first-line treatment of squamous non-small cell lung cancer (NSCLC) with the drug ® (Gisithamin) and platinum.
-
The correlation between diet and lifestyle and the incidence of glioma.
Time of Update: 2020-09-10
meta-analysis found that adequate vegetable intake may be a measure to prevent glioma, especially in Asian populations; the effects of fruit intake on the incidence of glioma are not fully studied, but the intake of the right amount of fruit can reduce the incidence of many other types of tumors.
-
The clinical development of tumor immunotherapy in China in the past 20 years presents these three major trends
Time of Update: 2020-09-10
article points out that a highly concentrated pipeline of research and development is related to the new drug development model of china's local biopharmaceutical companies - giving priority to products similar to clinically proven compounds for development can avoid the risk of drug development failure to a certain extent.
-
Cancer New Antigen DNA Vaccine and Anti-Cancer T-Cell Immune Stimulation! VB10. NEO's joint treatment of head and neck cancer with bempeg shows great potential!
Time of Update: 2020-09-09
August 16, 2020 // -- Two immuno-oncology companies,Vaccibody AS and Nektar Therapeutics, have jointly announced the evaluation of the individualized new antigen cancer vaccine VB10.NEO Joint CD12 Phase I/II clinical studies in patients treating patients with advanced head and neck squamous cell carcinoma (SCCHN) with the IL-2 pathogenic astigger bempegaldesleukin (bempeg) have been conducted in the first case of drug treatment.
-
Science: Study reveals role of microbiome in fighting cancer
Time of Update: 2020-09-09
study, published recently in the journal Science, suggests that combining immunotherapy with specific microbial therapies enhances the immune system's ability to recognize and attack certain melanoma, bladder and colorectal cancer cancer cells.
-
Solid tumor gene therapy! VBL's first anti-cancer gene therapy VB-111 to treat platinum-resistant ovarian cancer shows strong results!
Time of Update: 2020-09-09
this latest DSMC recommendation, together with the significant mitigation rates we observed in the first interim efficacy analysis and the survival benefits of VB-111 in Phase 2 trials in patients with platinum-resistant ovarian cancer, supports our confidence in OBAL.
-
Should patients with low-grade gliomas have early radiotherapy after surgery?
Time of Update: 2020-09-08
results showed that the postoperative early radiation therapy group in LGG patients had significantly longer progression survival than the delayed radiotherapy group when the disease progressed, but did not significantly extend the total survival period (OS).
-
Analysis of prognostic factors of diffuse midline glioma.
Time of Update: 2020-09-07
analysis of patients with diffuse mid-line glioma H3K27M mutations found that in patients with H3K27M mutations, PDGFRA amplification (P=0.010), 17p deficiency (P=0.008) and complex chromosome structures (P=0.044) were significantly associated with shorter total survival (Figure 1).
-
Detection of IDH1 and TRT initiation mutations for gliomas that are not clearly diagnosed for biopsies can avoid...
Time of Update: 2020-09-06
17 (61%) of the 28 biopsy-undiagnosed glioma pathological specimens detected IDH1 or pTERT mutations.
conclusions, the study showed that mutations in IDH1 and pTERT accounted for a higher proportion of patients with suspected diffuse gliomas that were not explicitly diagnosed in biopsies.
-
New cell therapy! Allogeneic active degenerative degenerative cells iixadencel combined with Shonitini first-line treatment of metastatic kidney cancer has strong efficacy!
Time of Update: 2020-09-06
recently, the company released the latest total lifetime (OS) data from its lead candidate therapy, the ilixadencel, in a joint targeting anti-cancer drug, Sutent, a generic name: sunitinib, Schoinidini; developed by Pfizer, for the first-line treatment of metastatic renal cell carcinoma (mRCC) Phase II MERECA clinical studies.
-
Tumor immunotherapy upgrade! AstraZeneta's New 4-Week Fixed Dose Program is under FDA priority review!
Time of Update: 2020-09-06
If sBLA is approved, Imfinzi may offer a new administration option (fixed dose 1500 mg, once every 4 weeks) in patients with non-excisive phase III NSCLC after chemotherapy and in patients with advanced bladder cancer who have previously been treated, consistent with the approved dose of broad-stage small cell lung cancer (ES-SCLC) (fixed dose 1500 mg).
-
Professor Yuan Xianglin: "CSCO Gastric Cancer Diagnosis and Treatment Guidelines" immunotherapy update shows cutting-edge evidence-based
Time of Update: 2020-09-06
results from the ATTRACTION-2 study in Taiwan, China, showed that Navuliyu monoantigen could bring significant survival benefits to patients with advanced stomach cancer in China treated with third- and post-line treatment.
-
The antibody drug Polivy, which targets CD79a, received NICE-recommended treatment for relapsed or incurable large B-cell lymphoma.
Time of Update: 2020-09-05
The National Institute for Health and Care Excellence (NICE) recommends combining Roche's antibody drug Polivy (polatuzumab vedotin) with rituximab and bendamustine to treat diffuse large B-cell lymphoma (DLBCL).
-
Major progress in immunotherapy for esophageal cancer! Merck's Keytruda + chemotherapy first-line treatment phase III clinical success!
Time of Update: 2020-09-05
August 20, 2020 / / -- Merck Co) recently announced that the evaluation of the anti-PD-1 therapy Keytruda (Corintha, generic name: pembrolizumab, Pabliju monoantigen) combined chemotherapy (shunplatin-5-fluorouracine (5-FU)) first-line treatment of local late stage or metastatic esophageal cancer key phase III KEYNOTE-590 trial reached the total survival period (OS) and non-progressive survival (PFS) 2 major endpoints.
-
Support Care Cancer: Exercise interventions may improve cognitive function in prostate cancer patients.
Time of Update: 2020-09-05
meta-analysis showed that exercise had social function in men with prostate cancer compared to the control group (Hedges' g s 0.35, 95% CI (0.193, 0.515), p slt;0 .001) and cognitive function (Hedges' g s 0.35, 95% CI (0.123, 0.575), p slt;0.01) have an overall beneficial effect.
-
Medicine: Non-amines can significantly reduce the risk of prostate cancer.
Time of Update: 2020-09-05
study, we conducted a systematic literature review and meta-analysis to assess the relationship between phosphonamide and prostate cancer.
results showed a significant correlation between the use of phosphonamide and prostate cancer, with a combined OR value of 0.70 ( 0.51, 0.96 ) .
-
Allogeneic CAR-T cell therapy treats leukemia and obtains FDA fast-track designation.
Time of Update: 2020-09-05
Precision Bioscience corporation announced that the U.S. Food and Drug Administration (FDA) has awarded its isometremic antigen-insignidant (CAR-T) cell therapy PBCAR0191 a fast-track designation for the treatment of advanced pregenicular B-cell acute lymphoblastic leukemia (B-ALL).
-
Cancer cell: Clinical challenge of immunosuper inhibitors.
Time of Update: 2020-09-05
IO Clinical Challenge Anti-Tumor Activity Although immunosuper inhibitors are unique in their ability to achieve long-term or even complete response, the fact is that most patients still do not benefit from treatment.
